Why Didn't Pfizer Stock Jump More After Winning Authorization for Its COVID Vaccine?
Pfizer (NYSE: PFE) received great news last Thursday that an advisory committee to the U.S. Food and Drug Administration (FDA) overwhelmingly recommended Emergency Use Authorization (EUA) for its COVID-19 vaccine. That news was followed by the FDA granting EUA to Pfizer's vaccine over the weekend. But Pfizer's shares slipped on both Friday and Monday after these positive developments. In this Motley Fool Live video recorded on Dec. 11, 2020, healthcare and cannabis bureau chief Corinne Cardina and Fool.com writer Keith Speights discuss why Pfizer stock didn't jump following the good news.
Source Fool.com
